328 related articles for article (PubMed ID: 35456049)
1. Genomic Hippo Pathway Alterations and Persistent YAP/TAZ Activation: New Hallmarks in Head and Neck Cancer.
Faraji F; Ramirez SI; Anguiano Quiroz PY; Mendez-Molina AN; Gutkind JS
Cells; 2022 Apr; 11(8):. PubMed ID: 35456049
[TBL] [Abstract][Full Text] [Related]
2. Targeting-YAP/TAZ therapies for head and neck cancer, directly or indirectly?
Feng XD
Hua Xi Kou Qiang Yi Xue Za Zhi; 2021 Oct; 39(5):493-500. PubMed ID: 34636195
[TBL] [Abstract][Full Text] [Related]
3. Hippo Pathway and YAP Signaling Alterations in Squamous Cancer of the Head and Neck.
Santos-de-Frutos K; Segrelles C; Lorz C
J Clin Med; 2019 Dec; 8(12):. PubMed ID: 31817001
[TBL] [Abstract][Full Text] [Related]
4. The potential role of YAP in head and neck squamous cell carcinoma.
Shin E; Kim J
Exp Mol Med; 2020 Aug; 52(8):1264-1274. PubMed ID: 32859951
[TBL] [Abstract][Full Text] [Related]
5. EGFR Regulates the Hippo pathway by promoting the tyrosine phosphorylation of MOB1.
Ando T; Arang N; Wang Z; Costea DE; Feng X; Goto Y; Izumi H; Gilardi M; Ando K; Gutkind JS
Commun Biol; 2021 Nov; 4(1):1237. PubMed ID: 34725466
[TBL] [Abstract][Full Text] [Related]
6. Assembly and activation of the Hippo signalome by FAT1 tumor suppressor.
Martin D; Degese MS; Vitale-Cross L; Iglesias-Bartolome R; Valera JLC; Wang Z; Feng X; Yeerna H; Vadmal V; Moroishi T; Thorne RF; Zaida M; Siegele B; Cheong SC; Molinolo AA; Samuels Y; Tamayo P; Guan KL; Lippman SM; Lyons JG; Gutkind JS
Nat Commun; 2018 Jul; 9(1):2372. PubMed ID: 29985391
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
García-Escudero R; Segrelles C; Dueñas M; Pombo M; Ballestín C; Alonso-Riaño M; Nenclares P; Álvarez-Rodríguez R; Sánchez-Aniceto G; Ruíz-Alonso A; López-Cedrún JL; Paramio JM; Lorz C
Oral Oncol; 2018 Apr; 79():55-63. PubMed ID: 29598951
[TBL] [Abstract][Full Text] [Related]
8. YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4.
Chen N; Golczer G; Ghose S; Lin B; Langenbucher A; Webb J; Bhanot H; Abt NB; Lin D; Varvares M; Sattler M; Egloff AM; Joh R; Uppaluri R; Emerick KS; Lawrence MS; Saladi SV
Cell Rep; 2022 Jun; 39(11):110970. PubMed ID: 35705032
[TBL] [Abstract][Full Text] [Related]
9. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma.
Shi H; Zou Y; Zhong W; Li Z; Wang X; Yin Y; Li D; Liu Y; Li M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15311-15322. PubMed ID: 37608027
[TBL] [Abstract][Full Text] [Related]
10. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
11. Transmembrane protein KIRREL1 regulates Hippo signaling via a feedback loop and represents a therapeutic target in YAP/TAZ-active cancers.
Gu Y; Wang Y; Sha Z; He C; Zhu Y; Li J; Yu A; Zhong Z; Wang X; Sun Y; Lan F; Yu FX
Cell Rep; 2022 Aug; 40(9):111296. PubMed ID: 36044856
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
13. Desmoglein-3 induces YAP phosphorylation and inactivation during collective migration of oral carcinoma cells.
Ahmad US; Parkinson EK; Wan H
Mol Oncol; 2022 Apr; 16(8):1625-1649. PubMed ID: 35000271
[TBL] [Abstract][Full Text] [Related]
14. Integrating Genetic Alterations and the Hippo Pathway in Head and Neck Squamous Cell Carcinoma for Future Precision Medicine.
Ando T; Okamoto K; Shintani T; Yanamoto S; Miyauchi M; Gutkind JS; Kajiya M
J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294681
[TBL] [Abstract][Full Text] [Related]
15. Role of the Hippo pathway and mechanisms for controlling cellular localization of YAP/TAZ.
Kwon H; Kim J; Jho EH
FEBS J; 2022 Oct; 289(19):5798-5818. PubMed ID: 34173335
[TBL] [Abstract][Full Text] [Related]
16. AXL activates YAP through the EGFR-LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma.
Okamoto K; Ando T; Izumi H; Kobayashi SS; Shintani T; Gutkind JS; Yanamoto S; Miyauchi M; Kajiya M
Oncogene; 2023 Sep; 42(39):2869-2877. PubMed ID: 37591955
[TBL] [Abstract][Full Text] [Related]
17. Hippo signaling impairs alveolar epithelial regeneration in pulmonary fibrosis.
Warren R; Lyu H; Klinkhammer K; De Langhe SP
Elife; 2023 May; 12():. PubMed ID: 37166104
[TBL] [Abstract][Full Text] [Related]
18. The Hippo effector TAZ promotes cancer stemness by transcriptional activation of SOX2 in head neck squamous cell carcinoma.
Li J; Li Z; Wu Y; Wang Y; Wang D; Zhang W; Yuan H; Ye J; Song X; Yang J; Jiang H; Cheng J
Cell Death Dis; 2019 Aug; 10(8):603. PubMed ID: 31399556
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Hippo/YAP/TAZ signalling pathway: Novel opportunities for therapeutic interventions into skin cancers.
Howard A; Bojko J; Flynn B; Bowen S; Jungwirth U; Walko G
Exp Dermatol; 2022 Oct; 31(10):1477-1499. PubMed ID: 35913427
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Regulation of Yap/Taz from Cellular Systems and Mouse Models.
Du W; Du W; Wan M; Zhou X; Xu X; Zheng L
Curr Stem Cell Res Ther; 2018; 13(1):16-25. PubMed ID: 28042766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
